FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact

The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.